Fox Run Management L.L.C. Boosts Holdings in The Clorox Company $CLX

Fox Run Management L.L.C. increased its position in shares of The Clorox Company (NYSE:CLX) by 143.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,213 shares of the company’s stock after buying an additional 6,609 shares during the quarter. Fox Run Management L.L.C.’s holdings in Clorox were worth $1,346,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in CLX. Simplicity Wealth LLC raised its position in Clorox by 157.3% in the 2nd quarter. Simplicity Wealth LLC now owns 18,316 shares of the company’s stock valued at $2,199,000 after purchasing an additional 11,198 shares in the last quarter. Raymond James Financial Inc. increased its stake in Clorox by 15.6% in the first quarter. Raymond James Financial Inc. now owns 269,926 shares of the company’s stock valued at $39,747,000 after purchasing an additional 36,352 shares during the last quarter. OneDigital Investment Advisors LLC purchased a new position in shares of Clorox in the 1st quarter valued at $247,000. Nordea Investment Management AB raised its stake in Clorox by 16.3% during the 2nd quarter. Nordea Investment Management AB now owns 484,352 shares of the company’s stock worth $57,827,000 after acquiring an additional 68,026 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in Clorox by 109.4% in the first quarter. AlphaQuest LLC now owns 11,873 shares of the company’s stock valued at $1,748,000 after acquiring an additional 6,203 shares during the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares of the company’s stock, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.63% of the stock is owned by company insiders.

Clorox Stock Performance

Clorox stock opened at $107.37 on Friday. The company has a market cap of $13.07 billion, a price-to-earnings ratio of 16.47, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The Clorox Company has a 12 month low of $106.14 and a 12 month high of $171.37. The stock’s 50-day moving average is $119.49 and its 200-day moving average is $124.82.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the previous year, the firm earned $1.86 earnings per share. Clorox’s revenue for the quarter was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd were given a $1.24 dividend. The ex-dividend date of this dividend was Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.6%. Clorox’s dividend payout ratio (DPR) is 77.86%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CLX. Zacks Research downgraded Clorox from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 28th. Wells Fargo & Company decreased their price target on Clorox from $125.00 to $117.00 and set an “equal weight” rating on the stock in a research note on Tuesday. BNP Paribas Exane decreased their price target on Clorox from $110.00 to $103.00 and set an “underperform” rating on the stock in a research note on Tuesday, November 4th. Citigroup lowered their price objective on shares of Clorox from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Finally, Barclays cut their price target on Clorox from $112.00 to $108.00 and set an “underweight” rating for the company in a report on Tuesday, November 4th. One research analyst has rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $125.69.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.